Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalbavancin for Gram-positive Infective Endocarditis
2026-526149-91-00Phase 3Authorised
- Sponsor
- Friedrich Schiller University Jena
- Start
- Jun 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of dalbavancin in endocarditis (IE) (2 arms), sponsored by Friedrich Schiller University Jena. Primary endpoint: Primary DOOR outcome at Day 90. Planned start Jun 2026; status: authorised.
02
Drugs
dalbavancin
03
Conditions
endocarditis (IE)
Beyond the preview
Go deeper on 2026-526149-91-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526149-91-00.